Aquestive Therapeutics, Inc. (NASDAQ:AQST) Receives Consensus Recommendation of “Buy” from Analysts

Shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST) have been given an average rating of “Buy” by the seven research firms that are covering the firm, MarketBeat.com reports. Six research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $11.00.

AQST has been the subject of several recent analyst reports. JMP Securities reaffirmed a “market outperform” rating and set a $9.00 price objective on shares of Aquestive Therapeutics in a report on Tuesday, October 8th. Leerink Partners raised their price target on Aquestive Therapeutics from $12.00 to $13.00 and gave the company an “outperform” rating in a report on Friday, October 25th. Cantor Fitzgerald began coverage on Aquestive Therapeutics in a research note on Tuesday, December 17th. They issued an “overweight” rating and a $17.00 price objective on the stock. Finally, HC Wainwright restated a “buy” rating and issued a $10.00 target price on shares of Aquestive Therapeutics in a research note on Friday, December 20th.

Aquestive Therapeutics Price Performance

Shares of AQST stock opened at $3.21 on Wednesday. The stock’s fifty day simple moving average is $3.93 and its 200 day simple moving average is $4.19. Aquestive Therapeutics has a one year low of $2.24 and a one year high of $6.23. The firm has a market cap of $292.68 million, a price-to-earnings ratio of -7.13 and a beta of 2.71.

Aquestive Therapeutics (NASDAQ:AQST) last issued its earnings results on Monday, November 4th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.01). The firm had revenue of $13.54 million for the quarter, compared to the consensus estimate of $12.69 million. During the same quarter in the previous year, the company earned ($0.03) EPS. On average, research analysts anticipate that Aquestive Therapeutics will post -0.46 earnings per share for the current year.

Hedge Funds Weigh In On Aquestive Therapeutics

Several large investors have recently made changes to their positions in AQST. State Street Corp increased its position in Aquestive Therapeutics by 52.1% in the third quarter. State Street Corp now owns 1,496,739 shares of the company’s stock worth $7,454,000 after purchasing an additional 512,682 shares during the period. Blue Owl Capital Holdings LP raised its stake in shares of Aquestive Therapeutics by 30.3% during the second quarter. Blue Owl Capital Holdings LP now owns 1,140,000 shares of the company’s stock worth $2,964,000 after buying an additional 265,000 shares during the last quarter. Bank of New York Mellon Corp acquired a new position in Aquestive Therapeutics in the second quarter valued at approximately $594,000. Verition Fund Management LLC bought a new position in Aquestive Therapeutics in the third quarter valued at approximately $995,000. Finally, Wellington Management Group LLP acquired a new stake in Aquestive Therapeutics during the 3rd quarter worth $922,000. Institutional investors and hedge funds own 32.45% of the company’s stock.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.